IGF-1 Peptide Guide: LR3, DES, and Mecasermin Explained

What IGF-1 is, and what it is not

IGF-1 (insulin-like growth factor 1) is the primary downstream signal of growth hormone (GH). GH binds its receptor on hepatocytes, which then secrete IGF-1 into circulation; that circulating, "endocrine" IGF-1 is what a standard blood test measures. A separate pool of IGF-1 is made locally by skeletal muscle, bone, and other tissues, acting in an autocrine or paracrine way that does not always track with serum levels. This distinction matters clinically: a normal serum IGF-1 does not guarantee normal local tissue signaling, and a low serum value does not always mean local tissue exposure is low.

IGF-1 should not be confused with growth hormone itself, with insulin, or with the research peptides marketed under IGF-1-adjacent names. IGF-1 LR3, IGF-1 DES, and mechano growth factor (MGF) are structurally related molecules studied mainly in cell culture and animal models. They are not the same product as mecasermin, and none carries an FDA-approved human indication as of this writing (verify current status before relying on this for a clinical decision, since regulatory status can change).

IGF-1 binds the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase structurally similar to the insulin receptor. Receptor binding activates two principal intracellular pathways: PI3K/Akt/mTOR, which drives protein synthesis and cell survival, and Ras/MAPK, which drives cell proliferation. This dual signaling explains both IGF-1's anabolic reputation and the reason its high or sustained elevation raises theoretical concerns about mitogenic (growth-promoting) effects on any pre-existing abnormal cells.

At high concentrations, IGF-1 can also weakly activate the insulin receptor. This cross-reactivity is the basis for the hypoglycemia risk associated with pharmaceutical IGF-1 dosing, discussed below.

IGF-binding proteins: why total IGF-1 is not the whole story

More than 99% of circulating IGF-1 is bound to one of six IGF-binding proteins (IGFBP-1 through IGFBP-6), which extend its half-life and regulate how much reaches receptors. IGFBP-3 carries the majority of bound IGF-1 in a large ternary complex with an acid-labile subunit (ALS); this complex is far longer-lived than free IGF-1, which circulates for only minutes once liberated from its binding proteins.

IGFBP-1 and IGFBP-2 are shorter-lived and respond acutely to nutrition and insulin status: fasting raises IGFBP-1 and lowers free IGF-1 availability, even when total serum IGF-1 is unchanged. This is one reason a malnourished patient can show a normal or even elevated GH pulse alongside a low free IGF-1 signal, the binding proteins, not GH secretion, are limiting IGF-1 action.

Local proteases released during tissue injury or inflammation can cleave IGFBP-3 and release free IGF-1 at the site of repair, independent of a change in total serum IGF-1. This local, injury-triggered liberation of IGF-1 is part of the biological rationale offered for muscle-repair peptides such as MGF, discussed below, though the human clinical relevance of manipulating this system pharmacologically remains unproven.

Serum IGF-1: how it is used diagnostically

Serum IGF-1 declines with age and is interpreted using age- and sex-adjusted standard deviation scores (SDS) rather than a single fixed "normal range," since absolute levels in a healthy 25-year-old and a healthy 65-year-old differ substantially. A low SDS in a symptomatic adult (fatigue, reduced lean mass, unfavorable lipid changes) can prompt evaluation for growth hormone deficiency, though guideline bodies including the Endocrine Society emphasize that IGF-1 alone is not sufficient for diagnosis; a GH stimulation test is generally required to confirm adult GH deficiency (Endocrine Society clinical practice guideline on GH deficiency in adults). A supranormal IGF-1, confirmed on repeat testing, is the standard initial screening finding for suspected acromegaly, a condition of chronic GH and IGF-1 excess usually caused by a pituitary tumor.

Recent scoping work on pediatric growth disorders has emphasized integrating IGF-1 biology with genetic and clinical phenotype data rather than treating IGF-1 as a stand-alone marker, reflecting a broader shift toward multi-factor diagnostic frameworks in this field (2026 systematic scoping review, PubMed). This is a research and diagnostic-framework observation, not a new treatment recommendation, and it applies specifically to pediatric growth-disorder evaluation rather than adult IGF-1 use.

The only FDA-approved IGF-1 drug: mecasermin (Increlex)

Mecasermin is recombinant human IGF-1, approved by the FDA for long-term treatment of severe primary IGF-1 deficiency (including Laron syndrome and related conditions) in pediatric patients. It is given by subcutaneous injection, dosed by body weight, and must be accompanied by a meal at each injection because of hypoglycemia risk; skipping a meal after dosing is a labeled concern. In the pivotal trial supporting approval, children treated with mecasermin grew faster than those on placebo over a defined treatment period, with hypoglycemia as the most frequently reported adverse event. Readers should confirm exact current dosing and labeled adverse-event rates against the FDA label rather than a secondary summary, since label details can be revised.

Mecasermin has also been studied in small trials outside its approved indication, including in ALS and HIV-associated lipodystrophy, without evidence sufficient to support an expanded approval. Active or suspected malignancy is a labeled contraindication, consistent with the mitogenic concerns discussed above. A related product that combined IGF-1 with its binding protein (mecasermin rinfabate) was previously marketed and later withdrawn from the US market; the reason for withdrawal is a commercial and regulatory detail that should be confirmed against current FDA records rather than assumed.

IGF-1 LR3, IGF-1 DES, and mechano growth factor: research reagents, not medicines

IGF-1 LR3 is a synthetic analog with structural changes near the binding-protein interaction site that greatly reduce its affinity for IGFBPs. Because it escapes sequestration by binding proteins, more of an administered dose remains in the free, active form for longer, which is the basis for its much longer reported half-life compared with native free IGF-1. This is a plausible pharmacologic mechanism supported by laboratory and animal data; it has not been established in controlled human trials.

IGF-1 DES is a truncated form of IGF-1 missing several N-terminal amino acids that are the main binding-protein attachment site. This truncation is reported to increase receptor affinity while nearly eliminating IGFBP binding, producing a short-acting, locally concentrated effect when injected intramuscularly. As with LR3, this is supported by preclinical and mechanistic data, not human trials.

Mechano growth factor (MGF) is a naturally occurring splice variant of the IGF-1 gene, transiently expressed in muscle after mechanical loading or injury. Laboratory work has proposed that its distinct E-domain peptide activates and expands the pool of satellite cells (muscle stem cells) before mature IGF-1 drives their differentiation into new muscle fibers. A stabilized, PEGylated form (pMGF) has been used in animal injury models to extend its otherwise very short activity window. Human trial data on MGF or pMGF are absent from the published literature to date.

None of these three analogs is FDA-approved for any human use, including bodybuilding, injury recovery, or anti-aging purposes. They are sold through research-chemical channels and gray-market peptide suppliers, dosed according to informal community protocols with no regulatory or clinical validation. Because they share IGF-1R signaling with mecasermin, the same theoretical concerns apply, hypoglycemia, fluid retention, acromegaloid tissue changes with chronic supraphysiologic exposure, and unresolved long-term mitogenic risk, without the manufacturing quality control, dosing precision, or safety monitoring that comes with an approved pharmaceutical product.

IGF-1 and cancer risk: what the evidence actually supports

Population studies have repeatedly found that people with higher circulating IGF-1 have modestly higher rates of certain cancers, including colorectal and premenopausal breast cancer, in some large pooled analyses. These are epidemiological associations describing populations, not individual risk predictions, and they do not establish a specific numeric threshold below which IGF-1 is proven safe. Readers should treat any specific odds ratio quoted for this relationship as a figure requiring verification against the primary paper rather than a fixed fact, since study populations, IGF-1 assay methods, and adjustment strategies vary considerably across the literature.

The clearest and most consistent human model of chronic IGF-1 excess is acromegaly, and current research continues to examine mechanisms linking acromegaly to elevated colorectal cancer risk, including possible roles for gut microbiota changes (2026 review, PubMed). This is disease-specific evidence from a condition of years-long, severe IGF-1 elevation; it does not directly predict the risk of short-term or moderate IGF-1 elevation from an unapproved analog, and no equivalent long-term human cancer-surveillance data exist for LR3, DES, or MGF users.

Because IGF-1 signaling suppresses apoptosis and promotes cell proliferation, the working clinical assumption is that any occult malignancy could theoretically grow faster in a chronically high-IGF-1 environment. This is why active or suspected malignancy is a labeled contraindication to mecasermin, and why endocrinologists managing GH or IGF-1 replacement typically target the lower half of the normal range rather than the upper limit.

The load-bearing paragraph on this page: IGF-1 is a normal, essential hormone whose FDA-approved pharmaceutical form (mecasermin) is restricted to a rare pediatric deficiency and dosed under direct medical supervision with meal timing and glucose monitoring built into the label. The research analogs marketed as IGF-1 LR3, IGF-1 DES, and mechano growth factor are not approved for any human use, have no published controlled human trials, and carry the same theoretical hypoglycemia and mitogenic risks as mecasermin without its manufacturing oversight or monitoring infrastructure. Anyone considering an IGF-1 product for reasons other than a diagnosed deficiency should treat that absence of human trial data as the central fact, not a footnote.

Safety concerns across all IGF-1 exposure

• Hypoglycemia. The most immediate and best-documented risk, arising from IGF-1's cross-reactivity with the insulin receptor at higher exposures. Applies to mecasermin and, mechanistically, to the unapproved analogs as well.
• Acromegaloid changes. Chronic supraphysiologic IGF-1 exposure, as seen in acromegaly, produces soft-tissue swelling, jaw and facial changes, carpal tunnel syndrome, and organ enlargement, some of which may not fully reverse.
• Fluid retention. IGF-1 increases renal sodium reabsorption, which can raise blood pressure and cause edema at doses above physiologic replacement.
• Mitogenic risk. Sustained receptor activation raises theoretical concern for accelerating growth of an undetected malignancy; active or suspected cancer is a contraindication on the mecasermin label.
• Unknown long-term profile for analogs. LR3, DES, and MGF carry no long-term human pharmacovigilance data of any kind.

Anyone experiencing symptoms of severe hypoglycemia (confusion, seizure, loss of consciousness) after any IGF-1-related product should seek urgent medical care; this is not a symptom to manage by self-adjusting a dose.

Decision framework: which IGF-1 question are you actually asking?

Readers arrive at IGF-1 content with very different situations. This framework separates them, because the evidence base, regulatory status, and appropriate next step differ sharply by category.

What is established, what is plausible, and what is not established

Established: IGF-1 is the principal mediator of GH's anabolic effects; serum IGF-1 is a standard, guideline-supported biomarker for GH deficiency and acromegaly screening; mecasermin is FDA-approved for severe primary IGF-1 deficiency in children with a known hypoglycemia risk; chronic severe IGF-1 excess (acromegaly) is associated with increased colorectal cancer risk and other systemic complications.

Plausible but unproven in humans: that IGF-1 LR3, IGF-1 DES, or MGF produce meaningfully better muscle growth or recovery outcomes in humans than what is seen in cell culture and animal models; that manipulating IGFBP-3 proteolysis pharmacologically has a favorable human risk-benefit profile; that a specific IGF-1 odds ratio for cancer risk applies uniformly across populations and IGF-1 assay methods.

Not established: any safe or effective human dosing regimen for IGF-1 LR3, IGF-1 DES, or MGF; long-term cancer or cardiovascular outcomes for people using these unapproved analogs; any FDA-approved indication for these analogs in adults for performance, recovery, or anti-aging purposes.